Varenicline decreases alcohol consumption in heavy-drinking smokers

Psychopharmacology

Volumn 223, Issue 3, 2012, Pages 299-306

  Mitchell, Jennifer M ^a,b   Teague, Candice H ^a   Kayser, Andrew S ^a,b   Bartlett, Selena E ^a   Fields, Howard L ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4 2; Abuse; Chantix; Double blind; Hazardous drinking; Smoking

Indexed keywords

ALCOHOL; COTININE; ETHYL GLUCURONIDE; PLACEBO; RIBOFLAVIN; VARENICLINE;

ADULT; AGGRESSION; AGITATION; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ANGER; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRINKING; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SMOKING; SMOKING CESSATION; SUICIDAL IDEATION; SUICIDE; TOBACCO DEPENDENCE; VIVID DREAM; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BENZAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH RECORDS, PERSONAL; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866743572     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2717-x     Document Type: Article

References (33)

1. Anton RF, Moak DH, Latham PK (1996) The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53:225-231
2. Appenzeller BM, Agirman R, Neuberg P, Yegles M, Wennig R (2007) Segmental determination of ethyl glucuronide in hair: A pilot study. Forensic Sci Int 173:87-92
3. Bito-Onon JJ, Simms JA, Chatterjee S, Holgate J, Bartlett SE (2011) Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-Administration in Sprague-Dawley rats. Addict Biol. 16(3):440-449
4. Bouza C, Angeles M, Magro A, Muñoz A, Amate J (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99:811-828
5. Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, Shaffer CL, Lowe J, RollemaH, Bartlett SE (2011) Partial agonists of the α3ß4 neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 36:603-615
6. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 215:655-663
7. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A (2011) A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 69:1075-1082
8. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Group VPS (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296:47-55
9. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991) The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 86:1119-1127
10. Heffernan TM, Moss M, Ling J (2002) Subjective ratings of prospective memory deficits in chronic heavy alcohol users. Alcohol Alcohol 37:269-271
11. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR (2010) Activation of α4 nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci 30:10169-10176
12. Howard J (1992) Subject recruitment and retention issues in longitudinal research involving substance-Abusing families: A clinical services context. NIDA Res Monogr 117:155-165
13. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Group VPS (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296:56-63
14. Lovibond SH, Lovibond PF (1995) Manual for the Depression Anxiety Stress Scales, 2nd ed. Psychology Foundation, Sydney
15. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E (2009) Varenicline reduces alcohol self-Administration in heavydrinking smokers. Biol Psychiatry 66:185-190
16. Mello NK, Mendelson JH, Palmieri SL (1987) Cigarette smoking by women: Interactions with alcohol use. Psychopharmacology (Berl) 93:8-15
17. Mitchell SH, de Wit H, Zacny JP (1995) Effects of varying ethanol dose on cigarette consumption in healthy normal volunteers. Behav Pharmacol 6:359-365
18. Moore TJ, Glenmullen J, Furberg CD (2010) Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother 44:1389-1394
19. Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768-774
20. Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M (2010) The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: A pilot study. Am J Addict 19: 401-408
21. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518
22. Room R (2004) Smoking and drinking as complementary behaviours. Biomed Pharmacother 58:111-115
23. Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, Lawhon D (2004) Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res 6:133-144
24. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 88:791-804
25. Schmitt G, Droenner P, Skopp G, Aderjan R (1997) Ethyl glucuronide concentration in serum of human volunteers, teetotalers, and suspected drinking drivers. J Forensic Sci 42:1099-1102
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini- International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33, quiz 34-57
27. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104:12518-12523
28. Tómasson K, Vaglum P (1995) A nationwide representative sample of treatment-seeking alcoholics: A study of psychiatric comorbidity. Acta Psychiatr Scand 92:378-385
29. Toneatto T, Sobell LC, Sobell MB (1992) Predictors of alcohol abusers' inconsistent self-reports of their drinking and life events. Alcohol Clin Exp Res 16:542-546
30. Toneatto A, Sobell LC, Sobell MB, Kozlowski LT (1995) Effect of cigarette smoking on alcohol treatment outcome. J Subst Abuse 7:245-252
31. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438-1442
32. Wright C, Moore R (1990) Disulfiram treatment of alcoholism. Am J Med 88:647-655
33. Wurst FM, Kempter C, Seidl S, Alt A (1999) Ethyl glucuronide-A marker of alcohol consumption and a relapse marker with clinical and forensic implications. Alcohol Alcohol 34:71-77